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Abstract
Marfan syndrome (MFS) is an autosomal dominant disease of the connective tissue that affects the ocular, skeletal and car-
diovascular systems, with a wide clinical variability. Although mutations in the FBN1 gene have been recognized as the cause 
of the disease, more recently other loci have been associated with MFS, indicating the genetic heterogeneity of this disease. 
We addressed the issue of genetic heterogeneity in MFS by performing linkage analysis of the FBN1 and TGFBR2 genes in 34 
families (345 subjects) who met the clinical diagnostic criteria for the disease according to Ghent. Using a total of six microsatel-
lite markers, we found that linkage with the FBN1 gene was observed or not excluded in 70.6% (24/34) of the families, and in 
1 family the MFS phenotype segregated with the TGFBR2 gene. Moreover, in 4 families linkage with the FBN1 and TGFBR2 
genes was excluded, and no mutations were identified in the coding region of TGFBR1, indicating the existence of other genes 
involved in MFS. Our results suggest that the genetic heterogeneity of MFS may be greater that previously reported.
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Marfan syndrome (MFS; MIM 154700) is a relatively 
common autosomal dominant hereditary disorder of con-
nective tissue (1:5,000-10,000 individuals) with prominent 
manifestations in the skeletal, ocular, and cardiovascular 
systems. Many affected individuals have a characteristic 
habitus with tall stature, long slender limbs (dolichostenom-
elia), arachnodactyly, scoliosis, and pectus excavatum or 
carinatum. Ectopia lentis affects up to 80% of individuals 
with MFS and is almost always bilateral (1-3). The leading 
cause of premature death in untreated individuals with 
MFS is acute aortic dissection, which follows a period of 
progressive dilatation of the ascending aorta (4-6). 
The disease is caused by mutations in the FBN1 gene 
at 15q21.1, encoding the large cysteine-rich extracellular 
matrix glycoprotein fibrillin-1, the major component of 
microfibrils. FBN1 spans a 230-kb genomic region with 65 
exons and about 600 different reported mutations spread 
throughout the gene, mostly specific to each affected fam-
ily (7-13).
In 2003, an unexpected link between fibrillin-1 mutations 
and increased transforming growth factor-β (TGF-β) signal-
ing was established in a mouse model for MFS, revealing 
a novel mechanism for the pathogenesis of the condition 
(14,15). Subsequently, it was found that the TGF-β receptor 
II gene (TGFBR2) was mutated in patients with MFS not 
linked to FBN1 (16). This provided the first genetic evidence 
of a direct link between abnormal TGF-β signaling and a 
human connective tissue disorder. Finally, it was proposed 
that mutations in the TGFBR1 or TGFBR2 gene lead to 
a different disease, Loeys-Dietz syndrome (LDS), with 
some clinical overlap with MFS (17). LDS is characterized 
by aortic dilatation, ocular hypertelorism, cleft lip/palate, 
arterial tourtoise, craniostenosis, and mental retardation. 
Nevertheless, there are reports of TGFBR1, TGFBR2, 
and FBN1 mutations in classical MFS, non-classical MFS, 
thoracic aortic aneurysms and dissections (TADD), and 
Shprintzen-Goldberg syndrome. In neonatal MFS, ectopia 
lentis and Weill-Marchesani syndrome, mutations only in 
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FBN1 have been reported, whereas mutations associated 
with LDS have been found exclusively in the TGFBR1 and 
TGFBR2 genes (18,19). 
At first, identification of mutations in the FBN1 gene 
appeared as the ultimate tool for confirmation of clinical 
diagnosis and risk assessment in MFS. As an alternative to 
the impractical direct identification of the disease-causing 
mutations in a gene as large as FBN1, in familial cases a 
successful approach to the molecular diagnosis is repre-
sented by linkage analysis using four intragenic microsatel-
lite markers (20). Their segregation in families allows the 
identification of the disease haplotype.
In this study, we addressed the issue of genetic hetero-
geneity of MFS phenotypes by analyzing 34 families in a 
large cohort of Brazilian patients who met the clinical diag-
nostic criteria for the disease. We found 6 families in which 
linkage of the MFS phenotype with FBN1 was excluded, 




Forty-seven MFS families (a total of 358 subjects) 
were referred to us by medical geneticists from the Medi-
cal Genetics Center (UNIFESP). All the probands met the 
diagnostic criteria for MFS (Ghent criteria) (6). The study 
was approved by the Institutional Ethics Committee of 
the Instituto de Biociências, Universidade de São Paulo, 
and all subjects gave written informed consent. Genomic 
DNA was extracted from leukocytes isolated from EDTA-
anticoagulated whole blood (21).
Polymorphic markers
Four microsatellite markers, mts1, mts2, mts3, mts4, 
mapped to intron 1, 5, 28, and 43 of FBN1, respectively, 
were used for linkage analysis as previously described 
(20). The microsatellite markers used for TGFBR2 were 
D3S3727 (an intragenic TGFBR2 marker) and D3S3567. 
PCR primers and conditions were those described else-
where (18). Fluorescently labeled PCR products were 
analyzed with the MegaBACE 1000 DNA Analysis system 
using the Genetic Profiler software, version 1.5 (Amersham 
Biosciences, Sweden). 
Mutation analysis 
The coding regions of the TGFBR1 gene were PCR 
amplified from genomic DNA, and PCR products were 
subjected to direct sequencing (18,22).
Lod score calculations
Lod score was calculated using the computer packages 
MLINK of the FASTLINK version 4.2 for two-point linkage 
analysis (23), and MERLIN for multipoint analysis (24). The 
disease was coded as fully penetrant, while the disease 
allele frequency was set at 0.0001. Meiotic recombination 
frequencies were considered to be equal for males and 
females. Allele frequencies for the microsatellite markers 
were calculated by the software based on data from each 
family. Maximum lod score for each family was calculated 
by simulation, considering that all meioses were informative. 
Families were scored according to segregation of markers 
and phenotypes as: linkage (lod score ≥3.0); linkage not 
excluded (-2 < lod score < 3.0), or linkage excluded (lod 
score < -2).
Statistical analyses 
Statistical analysis was performed using the BioEstat 
software version 5.0. The yield of mutation detection in 
probands with involvement in each separate organ sys-
tem was confirmed by the Pearson chi-square test, or the 
Fisher exact test for small samples. A P value of <0.05 was 
considered to be significant.
Results
A total of 358 affected and unaffected individuals from 47 
unrelated families were clinically assessed (Supplementary 
Table A). Although all probands met the Ghent diagnostic 
criteria for MFS, the clinical phenotype varied within and 
between families, as expected. The classic skeletal pheno-
type was observed in all 47 families, whereas in 67.6%, at 
least 1 individual had ectopia lentis, and in 82.3%, at least 
1 individual showed dilatation of the aorta (Supplementary 
Table A).
Thirty-four families presented enough individuals for 
linkage studies to be performed. Since most of the families 
were not large enough to obtain a lod score above 3.0, we 
compared the lod score obtained for each family with the 
theoretical maximum lod score possible for that family (Table 
1). The microsatellite marker mts3 was not informative in 
many individuals, and was thus excluded from the analysis 
(data not shown). Initially we sought to identify those fami-
lies where linkage to FBN1 could be excluded. We could 
not exclude linkage of the FBN1 haplotype with the MFS 
phenotype in 25 families (70.6%). A lod score greater than 
3.0 was obtained for 1 of these families (family 7; Table 1). 
In the other families, the results of lod scores were below 
3.0 due to the small number of individuals available for 
analysis. In 4 families (11.76%) the FBN1 gene markers 
were not informative, and thus the analysis was inconclusive. 
Finally, in 6 families (17.64%), we excluded segregation of 
FBN1 with the phenotype. 
The 6 families excluded for linkage with FBN1 were 
studied with polymorphic markers linked to the TGFBR2 
gene. In one family (family 43), linkage with the D3S3727 
marker was not excluded, and one family was not in-
formative for both TGFBR2 markers. However, in 4 of 
the 6 families (families 4, 15, 37, and 42; Table 1) we 
excluded segregation of TGFBR2 with the phenotype. 
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Probands of these 4 families were screened for muta-
tions in the coding region of TGFBR1, but no alteration 
was identified. 
We compared the frequency of major manifestations in 
each of the three affected systems in the families whose 
phenotype segregated with FBN1 with those that did not 
segregate with FBN1 (Table 2). We found no significant 
difference in the frequency of cardiac and skeletal signs, 
but the major manifestations in the ocular system were 
significantly more frequent in families segregating with 
FBN1 than in those that did not segregate with this gene 
(Table 2).
Table 1. Linkage analysis of the Marfan syndrome phenotype with the FBN1 and TGFBR2 genes.
Family* Lod score FBN1 (MERLIN) Lod score TGFBR2 (MERLIN) Max. lod score (MERLIN) Result FBN1 Result TGFBR2
1 (4) -3.221 N/INF 0.3 EXCL N/INF
2 (23) 2.104 NE 4.2 N/EXCL NE
3 (5) 0.6 NE 0.601 N/EXCL NE
4 (4) -3.221 -3.221 0.3 EXCL EXCL
5 (6) 0.600 NE 0.602 N/EXCL NE
6 (11) 1.2 -5.754 1.204 N/EXCL EXCL
7 (26) 3.911 NE 3.912 LINK NE
8 (9) 0.778 NE 1.204 N/EXCL NE
9 (18) 1.929 -9.893 1.929 N/EXCL EXCL
13 (5) 0.6 -2.620 0.602 N/EXCL EXCL
14 (4) 0.598 NE 0.598 N/EXCL NE
15 (10) -5.33 0.259 0.602 EXCL EXCL
16 (6) 0.147 -3.272 0.147 N/EXCL EXCL
17 (6) 0.536 NE 0.578 N/EXCL NE
18 (19) N/INF -8.416   N/INF N/INF EXCL
19 (16) 0.283 NE 2.408 N/EXCL NE
20 (15) 0.461 NE 0.593 N/EXCL NE
22 (5) 0.6 NE 0.602 N/EXCL NE
23 (11) 1.504 NE 1.504 N/EXCL NE
24 (14) 1.2 NE 1.203 N/EXCL NE
28 (3) 0.3 -3.221 0.3 N/EXCL EXCL
29 (11) 1.5 NE 1.503 N/EXCL NE
30 (3) 0.3 NE 0.3 N/EXCL NE
31 (14) 0.903 NE 0.903 N/EXCL NE
33 (5) 0.6 NE 0.602 N/EXCL NE
34 (11) 0.178 NE 0.286 N/EXCL NE
35 (16) -1.381 NE -0.537 N/EXCL NE
37 (12) -3.445 -3.133 1.158 EXCL EXCL
38 (3) N/INF NE   N/INF N/INF NE
40 (8) N/INF NE   N/INF N/INF NE
42 (27) -3.659 -9.03 3.421 EXCL EXCL
43 (4) -3.095 0.601 0.601 EXCL N/EXCL
45 (6) N/INF -2.201 0.710 N/INF EXCL
46 (5) 0.130 NE 0.139 N/EXCL NE
*The number of family members is given within parentheses. LINK = phenotype linked with the gene (lod score ≥3.0); N/EXCL = link-
age of phenotype with the gene was not excluded; EXCL = linkage of phenotype with the gene was excluded; N/INF = not informative; 
NE = not evaluated.
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Supplementary Table A. Clinical and genetic assessment of Marfan syndrome patients in 47 families.
Family Patient Ocular Cardiac Skeletal Gene
 EL MYO AO DIL MR >5 signs FBN1 TGFBR2
1 II-1 - + - - + EXCL N /INF
II-1 - - - - +
II-2 - + + + +
2 II-6 - - + - - N/EXCL NE
III-3 - + + + +
III-6 - - + + -
IV-4 - + + + +
IV-5 NE NE NE NE +
IV-8 - - - - +
3 I-2 + + + + + N/EXCL
II-2 + + + + +
4 I-1 - + + + + EXCL EXCL
II-1 - + + + +
II-2 - + + + +
5 I-2 + - + + + N/EXCL NE
II-1 + - + + +
II-2 + - + + +
II-3 - - - - -
II-4 NE NE NE NE NE
6 I-2 + + + + + N/EXCL EXCL
II-6 - + + + +
II-7 - + + + +
II-8 - + + + +
II-10 - + + + +
7 I-2 NE NE + + + LINK NE
II-1 NE NE NE NE +
III-1 - - + + +
8 II-1 + - + + + N/EXCL NE
III-1 - - - - +
III-3 + - + + +
9 IV-5 + - - + + N/EXCL EXCL
III-4 - - + - +
IV-1 - - - - +
IV-2 - + + - +
10 I-1 NE NE NE NE + NE NE
11 I-1 NE NE NE NE + NE NE
12 I-1 NE NE NE NE + NE NE
13 I-1 - + - + -/+ N/EXCL EXCL
II-2 + - + + +
III-1 - - + + +
III-2 - - NE NE +
14 II-1 + + - + + N/EXCL NE
II-2 - - - + +
II-3 - - - + +
15 II-4 - + + + + EXCL EXCL
III-5 - - + + +
III-6 - + - + +
Continued on next page
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Supplementary Table A continued.
Family Patient Ocular Cardiac Skeletal Gene
 EL MYO AO DIL MR >5 signs FBN1 TGFBR2
16 II-1 - + NE NE + N/EXCL EXCL
II-3 - + NE NE +
II-5 - + + - +
III-1 - + + + +
17 II-2 + + + + + N/EXCL NE
II-4 - + + + +
III-1 - + + + +
III-2 - - + + +
18 II-1 - + + - + N/INF EXCL
II-2 + - + + +
II-4 + - + + +
III-4 NE NE NE NE -/+
III-6 + - + + +
III-8 + - - - +
III-9 NE NE NE NE -/+
19 II-3 NE NE + + + N/EXCL NE
II-7 NE NE - + +
II-11 + - + + +
III-4 NE NE - + +
III-7 NE NE NE NE +
III-8 - - - + +
III-9 - + - + +
20 II-4 + - - + + N/EXCL NE
III-1 + - - + +
II-1 - + - + +
III-4 + - - + +
III-5 NE NE NE NE +
III-6 NE NE NE NE +
21 I-1 NE NE NE NE + NE NE
22 III-2 + - - - + N/EXCL NE
III-4 + - - + +
23 II-6 - + + - + N/EXCL NE
III-1 + + + - +
III-2 + - + + +
III-3 - + + + +
III-5 NE NE NE NE +
24 II-1 NE NE NE NE + N/EXCL NE
III-7 + + - + +
25 I-1 NE NE NE NE + NE NE
26 I-1 NE NE NE NE + NE NE
27 I-1 NE NE NE NE + NE NE
28 I-1 - + + - + N/EXCL EXCL
II-1 + + - + -/+
II-2 + + + + +
29 III-2 + - + - + N/EXCL NE
III-3 - + - + +
III-8 - + + - +
Continued on next page
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Supplementary Table A continued.
Family Patient Ocular Cardiac Skeletal Gene
 EL MYO AO DIL MR >5 signs FBN1 TGFBR2
30 I-2 + - - - + N/EXCL NE
II-1 + - + - +
II-2 + - - + +
31 II-8 + - + - + N/EXCL NE
III-4 - - + + +
III-5 + + + + +
32  I-1 NE NE NE NE + NE NE
33 II-3 + - - + + N/EXCL NE
IV-1 + - + + +
34 III-4 - - + + + N/EXCL NE
III-6 - + + - -/+
II-4 - + + - +
35 III-4 + - + - + N/EXCL NE
II-8 - + NE NE +
II-4 - + NE NE +
II-6 - + + - +
III-8 - + NE NE +
II-3 - + + - +
36 I-1 NE NE NE NE + NE NE
37 III-3 - - + - + EXCL EXCL
IV-1 NE NE NE NE +
III-5 NE NE NE NE +
38 II-1 - + + - + N/INF NE
I-1 - + + - +
39 I-1 NE NE NE NE + NE NE
40 III-1 + - + - + N/INF NE
III-2 + + - - +
II-2 + - - + +
41 I-1 NE NE NE NE + NE NE
42 II-12 NE NE + - + EXCL EXCL
II-6 NE NE + - +
II-8 - + - - -
II-10 - - - + +
III-7 - - - - +
III-5 - + NE NE +
III-16 - + NE NE +
III-17 - + NE NE +
43 II-5 - - - + + EXCL N/EXCL
I-3 - - - + -
44 I-1 NE NE NE NE + NE NE
45 IV-2 + - + - + N/INF EXCL
46 III-1 - + NE NE + N/EXCL NE
II-3 - + NE NE +
II-5 + + - + +
47 I-1 NE NE NE NE + NE NE
EL = ectopia lentis; MYO = myopia; AO DIL = aorta dilatation; MR = mitral reflux; N/EXCL = linkage of phenotype 
with the gene was not excluded; LINK = phenotype linked with the gene (lod score ≥3.0); EXCL = linkage of 
phenotype with the gene was excluded; N/INF = not informative; NE = not evaluated.
